Table 2.  Disease-modifying drugs in single trials that included more than 1 neurodegenerative disorder.,,,,,,,,,,,,
Drug,Trial,Phase,Diagnosis,Number of Participants,Duration of Trial,Primary Outcome(s),Biomarker Outcome(s),Year Registered,Status,,,
Nicotinamide riboside,NCT04430517,Early P1,"AD, MCI",50,"Baseline, 6 and 12 w, pre- and post- 1000 mg NR daily",Changes in brain NAD+; Changes in brain redox state; Changes in mitochondrial function; Changes in antioxidant glutathione (GSH) levels; Changes in cognitive status; Changes in functional status,,2020,2021; Recruiting,,,
Dasatinib + Quercetin,NCT04685590,P2,"MCI, AD",48,Baseline to Week 48,Serious Adverse Events (SAEs) and Adverse Events (AEs) in treatment group as compared to placebo group; Change in cellular senescence blood marker Senescence-Associated Secretory Phenotype (SASP) composite score; Change in cellular senescence blood marker Cluster of Differentiation 3 (CD3) in blood; Change in cellular senescence blood marker cyclin-dependent kinase inhibitor 2A (p16INK4A+) in blood; Change in cellular senescence blood marker T cells in blood; Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) slope; Change in the 14 - item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog 14) slope; Change in Positron Emission Tomography (PET) - Computed Tomography (CT) - brain tau pathology,,2020,2021; Not yet recruiting,,,
Nicotinamide,NCT03061474,P2,"MCI, AD",48,12 Months,Change in p-tau 231; Change in p-tau 181; Change in total tau,,2017,2021; Recruiting,,,
Donepezil,NCT04730635,P1,"AD, MCI",36,Up to approximately Week 8,Percentage Change From Baseline in Correct Responses on the One Card Learning (OCL) Task to Week 8; Percentage Change From Baseline in the Overall Standard Deviation (sd) in Average OCL Task (Arcsine Square Root Transformed) to Week 8; Percentage of Correct Responses on the OCL Task,,2021,2021; Recruiting,,,
Psilocybin,NCT04123314,Early P1,"MCI, AD",20,Baseline and 2 w after second psilocybin session,Change in Cornell Scale for Depression in Dementia (CSDD) score; Change in Quality of Life Alzheimer's Disease (QOL-AD) scale score,,2019,2021; Recruiting,,,
Posiphen,NCT04524351,P1/P2,"PD, AD",68,Baseline to 25±2 d,Incidence of Treatment-Emergent Adverse Events; Concentration of Posiphen in Plasma; Changes in Functional Impairment; Changes in Cognition,,2020,2021; Recruiting,,,
AZD0328,NCT04810104,P2,"MCI, PD",160,From baseline to week 12 (end of treatment period),"Change in Attentional Intensity Index composite factor score from baseline to week 12; Change in Attentional Intensity Index composite factor score from baseline to week 6; Change in Sustained Attention Index composite factor score from baseline to week 6 and week 12; Change in Working Memory Index composite factor score from baseline to week 6 and week 12; Screening/Baseline whole-brain and regionally specific brain volumes as predictors of treatment response; Screening/Baseline whole-brain perfusion as well as perfusion in ROIs as predictors of treatment response; Change in Episodic Memory Index composite factor score from baseline to week 6 and week 12; Change in Memory Speed Retrieval Index composite factor score from baseline to week 6 and week 12; Change in MoCA score from screening to week 12; Change in Sustained Attention Index composite factor score from week 12 to week 16; Change in Working Memory Index composite factor score from week 12 to week 16; Change in Episodic Memory Index composite factor score from week 12 to week 16; Change in Memory Speed Retrieval Index composite factor score from week 12 to week 16; Change in MDS-UPDRS Part III motor examination subscale score from baseline to week 12; Change in total score from the Non-Motor Symptom Scale from baseline to week 12; Change in total score from the 39-item Parkinson's Disease Questionnaire from baseline to week 12; Change in MCI-CGIC from baseline to week 12; Change in depression and anxiety subscale scores from the HADS from baseline to week 12; Incidence, nature and severity of AEs and SAEs during treatment period; Incidence of dosage reduction or treatment discontinuation during treatment period; Incidence of clinically significant changes or abnormal electrocardiogram (ECG) assessments, vital sign measurements and clinical laboratory values during treatment period; Changes in whole-brain and regionally specific brain volumes from baseline/screening to week 12; Changes in whole-brain perfusion as well as perfusion in regions of interests (ROIs) from baseline/screening to week 12; Changes in functional resting-state connectivity of the large-scale cognitive brain networks from baseline/screening to week 12; Screening/Baseline functional resting-state connectivity of the large-scale cognitive brain networks as predictors of treatment response; Placebo-controlled change in levels of exploratory blood-based biomarkers for neuroprotection and/or disease modification changes; Change in levels of study medication in blood from baseline to week 12",,2021,2021; Not yet recruiting,,,
Senicapoc,NCT04804241,P2,"AD, MCI",55,"Baseline, Week 26, Week 52","Change from Baseline in Trails B score; Change from Baseline in the Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog 13) score; Change from Baseline to Week 52 in levels of Cerebrospinal fluid (CSF) biomarkers: IL-1β, IL-6, TNF-α, MCP-1, and IL-10; Change from Baseline to Week 52 in levels of serum biomarkers: IL-6, TNF-α, MCP-1, and IL-10 and high sensitivity C-Reactive protein; Change from Screening in the Clinical Dementia Rating (CDR) sum of boxes score; Change from Baseline in the Everyday Cognition (ECog) score; Change from Screening in Montreal Cognitive Assessment (MoCA) score; Change from Baseline to Week 52 in Spanish English Neuropsychological Assessment Scales (SENAS) memory score; Change from Baseline to Week 52 in Spanish English Neuropsychological Assessment Scales (SENAS) executive composite score; Change from Baseline in Bushcke Cued Selective Reminding Task (CSRT) score; Change from Baseline in Verbal fluency (semantic) score; Change from Baseline in Verbal fluency (letter) score; Change from Baseline to Week 52 in Brain MRI measures of total grey matter.; Change from Baseline to Week 52 in Brain MRI measures of total brain volume.; Change from Baseline to Week 52 in Brain MRI measures of white matter hyperintensities.; Change from Baseline to Week 52 in total grey matter florbetaben binding on amyloid Positron Emission Tomography (PET); Change from Baseline in Cognitive Event Related Potential (ERP) measures of P600 word repetition.; Change from Baseline in Cognitive Event Related Potential (ERP) measures of alpha suppression effect.; Change from Baseline in Cognitive Event Related Potential (ERP) measures of anti-coupling between early theta and late alpha/beta activity.",,2021,2021; Not yet recruiting,,,
AltoidaML,NCT04701177,,"MCI, AD",500000,60 m of follow up,Change in Diagnostic Area Under the Receiver Operating Characteristic Curve (ROC-AUC),,2021,2021; Not yet recruiting,,,
Canakinumab,NCT04795466,P2,"AD, MCI",90,Baseline through to 24 w,Change from baseline in cognition as measured by the Neuropsychological Test Battery (NTB) total score; Number of participants who experience adverse events and serious adverse events; Change from baseline in microglia activation as measured by Positron-Emission Tomography-Translocator Protein 18kDa - microglia activation; Change from baseline in neuropsychiatric symptoms as measured by the Neuropsychiatric Inventory (NPI) total score; Change from baseline in function (activities of daily living) as measured by the Everyday Cognition (eCog) total score; Change from baseline in memory as measured by the total Neuropsychological Test Battery memory composite score and change from baseline in executive function as measured by the total Neuropsychological Test Battery executive function composite score; Change from baseline in pharmacokinetic concentrations and immunogenetic anti-agent antibody levels in serum and/or plasma and/or cerebrospinal fluid,,2021,2021; Not yet recruiting,,,
"Accelerometer, Midodrine or atomoxetine pill",NCT04782830,N/A,"PD, MSA",29,7 d of treatment or placebo period,Total standing time measured by an accelerometer; Orthostatic symptoms; Total number of steps measured by an accelerometer; Total walking time measured by an accelerometer,,2021,2021; Recruiting,,,delete
Apomorphine,NCT04786158,,"CBD, PSP",7,6 m,Effects of subcutaneous apomorphine on pain; Effects of subcutaneous apomorphine on quality of life,,2021,2021; Completed,,,
"Dasatinib, Quercetin",NCT04785300,P1/P2,"MCI, AD",20,11 w,Safety and Tolerability of 11 week of intermittent D+Q treatment,,2021,2021; Not yet recruiting,,,
Rapamycin,NCT04629495,P2,"AD, MCI",40,Baseline to 12 m,Number of adverse events; Change in glucose level; Change in albumin; Change in carbon dioxide or bicarbonate (CO2); Change in calcium; Central nervous system penetration of rapamycin; Change in Cognition using preclinical Alzheimer's Cognitive Composite 5 (PACC5); Change in Cognition using Clinical Dementia Rating Scale sum of Boxes (CDR-SOB); Change in Functional status; Change in Neuropsychiatric symptoms; Change in Gait Speed; Change in Grip Strength; Change in CSF amyloid beta; Change in cerebral glucose metabolism; Change in Brain Volumetry,,2020,2021; Not yet recruiting,,,
CORT108297,NCT04601038,P2,"AD, MCI",52,After 2 w of treatment,"Memory as assessed by pattern separation task performance after 2 weeks of treatment with CORT108297; Memory as assessed by the Hopkins Verbal Learning Test-Revised Edition (HVLT-R) after 2 weeks of treatment with CORT108297; Executive functioning as assessed by the Trail Making Test (TMT), part B after 2 weeks of treatment with CORT108297; Executive functioning as assessed by the Digit Span Task (digit span backwards) after 2 weeks of treatment with CORT108297",,2020,2021; Recruiting,,,
SNK01,NCT04678453,P1,"AD, MCI",21,"Baseline, Week 11, End of Study (Week 22)","To determine the safety profile of SNK01 monotherapy in patients with mild cognitive impairment (MCI) or Alzheimer's Disease by monitoring for adverse events.; To determine the tolerability of SNK01 monotherapy in patients with mild cognitive impairment (MCI) or Alzheimer's Disease by monitoring for adverse events.; To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of SNK01 monotherapy.; To assess preliminary efficacy of SNK01 measured by Alzheimer's Disease Assessment Scale Cognitive subscale (ADAS-Cog).; To assess preliminary efficacy of SNK01 measured by Mini-Mental Status Exam (MMSE).; To assess preliminary efficacy of SNK01 measured by Clinical Dementia Rating Scale: Sum of Boxes (CDR-SB).; To assess preliminary efficacy of SNK01 measured by Alzheimer's Disease Composite Score (ADCOMS).; To assess preliminary efficacy of SNK01 measured by cerebrospinal fluid (CSF) biomarkers: amyloid beta 42, T-tau and P-tau.",,2020,2021; Recruiting,,,
Metformin,NCT04220021,P2,"FTDLD, ALS",18,Baseline through Week 52,Number of subjects with treatment-emergent adverse events [Safety and Tolerability]; Change in RAN protein levels; Change in ALS Functional Rating Scale (ALSFRS-R) score,,2020,2021; Recruiting,,,
Spironolactone,NCT04522739,P4,"MCI, AD",30,"Baseline, Month 6, Month 12",Change in Digit Span Test Score; Count of Adverse Events; Attrition rate; Change in Trail Making Test Part A Score; Change in Trail Making Test Part B Score; Change in Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall Score; Change in Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed Recall Score; Change in Hopkins Verbal Learning Test-Revised (HVLT-R) Recognition Discrimination Index Score; Change in Montreal Cognitive Assessment (MoCA) Score; Change in NIH Toolbox Cognitive Battery - Cognitive Function Composite Score,,2020,2021; Not yet recruiting,,,
TSB Axo,NCT04736017,N/A,"MCI, PD",48,assessed every second or third day during the intervention period (d 1-14 and 29-41),Change in objective EDS; Difference in CSF alpha-synuclein; Change in verbal episodic memory performance; Difference in CSF tau; Subjective EDS; Sustained attention; Vigilance; Subjective nocturnal sleep quality; Fatigue; Executive Function; Attention performance; Plasma biomarkers; CSF biomarkers; Subjective sleep quality; Subjective mood; Subjective momentary sleepiness; Digital biomarkers; Sleep intensity; Depressive symptoms; Verbal episodic and visuospatial memory function; Quality of life questionnaire; Motor symptoms; Focused motor assessment,,2021,2021; Not yet recruiting,,,device
"Midodrine, Abdominal compression, sham compression",NCT04620382,Early P1,"MSA, PD",31,1 hour post-intervention tilt table test,Hemodynamic markers of cardiovascular risk,,2020,2021; Recruiting,,,
Zoledronic Acid 5Mg/Bag 100Ml Inj,NCT03924414,P4,"MSA, PD, DLB, PSP",3500,2 years,Number of Participants Hip Fractures; Mortality; Number of Participants with Clinical Fractures,,2019,2021; Recruiting,,,
Emtriva Capsule,NCT04500847,P1,"MCI, AD",35,Screening phase to month 6 after first treatment,"Number of participants with treatment emergent adverse events (TEAE's) in the treatment group will be compared to the placebo group; Change from baseline in key inflammatory biomarkers; Tumor necrosis factor-alpha (TNF-α), Interleukin 1-beta (IL-1β), and Interferon-alpha (IFN-α); Change in Mini Mental State Examination (MMSE) Total Scores; Change from baseline in Clinical Dementia Rating (CDR); Change from baseline in Alzheimer's Disease Assessment Scale-cognitive (ADAS-Cog -13); Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL); Change from baseline in Free and Cued Selective Reminding Test (FCSRT+IR) with delayed recall; Change from baseline in cerebrospinal fluid (CSF) phosphorylated tau/amyloid beta 42 (pTau/Aβ42) ratios",,2020,2021; Not yet recruiting,,,
"Altoida: neuropsychological, MRI, EEG and CSF biomarkers",NCT02843529,N/A,"MCI, AD",548,"baseline, 6, 12, 24, 36 and 42 m of follow up",Change From Baseline in Clinical Measure 7; Change From Baseline in Clinical Measure 6; Change From Baseline in Clinical Measure 5; Change From Baseline in Clinical Measure 4; Change From Baseline in Clinical Measure 3; Change From Baseline in Clinical Measure 2; Change From Baseline in Clinical Measure 1; Change of CSF Biomarkers Tau and ptau181 Values; Changes in Driving Breaking Force; MRI (Optional); Change From Baseline in Cognitive Measure; Changes in Driving Violations; Changes in Driving Direction; Changes in Driving Acceleration Velocity; Change of Brain Amyloid Deposition; Total Abeta 1-42 (Aβ42) Amyloid Deposition; Secondary Resting State Auditory Oddball ERP Endpoints; Secondary Resting State EEG Endpoints; Change in Diagnostic Area Under the Receiver Operating Characteristic Curve (ROC-AUC),,2016,2021; Completed,,,delete
[11C]MPC6827,NCT04575727,Early P1,"AD, ALS",40,Up to 48 hours from injection,Biodistribution of [11C]MPC6827; Estimation of clearance of [11C]MPC6827,,2020,2021; Recruiting,,,biomarker
TD-9855,NCT02705755,P2,"MSA, PD",34,Up to approximately 168 d for Part C,Seated systolic blood pressure; Adverse Events; Orthostatic hypotension symptoms,,2016,2021; Completed,,,
ABvac40,NCT03461276,P2,"AD, MCI",120,18 m,Incidence of treatment-emergent adverse events [safety and tolerability]; Immune response,,2018,"2021; Active, not recruiting",,,
TMS,NCT03224988,,"AD, MCI",60,3 years,Establish the structural basis for bilateral brain interactions in healthy older adults.; Establish the structural basis for bilateral brain interactions in MCI-AD older adults.; Establish the temporal dynamics of cross-hemispheric communication in normal aging using unilateral TMS; Establish the temporal dynamics of cross-hemispheric communication in normal aging using bilateral TMS; Establish the temporal dynamics of cross-hemispheric communication in normal aging using EEG; Establish the temporal dynamics of cross-hemispheric communication in MCI-AD using unilateral TMS; Establish the temporal dynamics of cross-hemispheric communication in MCI-AD using bilateral TMS; Establish the temporal dynamics of cross-hemispheric communication in MCI-AD using EEG,,2017,2021; Recruiting,,,device
"Cannabis, Medical",NCT03944447,P2,"PD, CTE, ALS",200000,Five years,Prevention of COVID-19; Treatment of COVID-19; Treatment of Symptoms; Cannabis Impact on Quality of Life; Cannabis Route and Dosing; Monitoring Adverse Events,,2019,2020; Recruiting,,,
13C6 Leucine,NCT03545126,,"FTDLD, CBD, PSP",32,6 m,CSF Tau Absolute Concentration; Tau Production Rate; Tau Fractional Turnover Rate (FTR),,2018,2020; Recruiting,,,
repetitive transcranial magnetic stimulation (rTMS),NCT04045990,N/A,"MCI, AD",40,Up to 5 w,Boston Naming Test; Western Aphasia Battery-repetition; Western Aphasia Battery-reading comprehension; Western Aphasia Battery-spelling; Controlled Oral Word Association Test; Cambridge Semantic Battery; The Northwestern Anagram Test; Picture Description Test; Changes in intrinsic functional connectivity,,2019,2020; Recruiting,,,device
Levetiracetam,NCT04643327,P2,"PD, MCI",28,Immediately after 2 w of treatment,Pattern separation performance (behavioural outcome); Hippocampal DG/CA3 subfield activity,,2020,2020; Not yet recruiting,,,
"Saline, Insulin detemir, Insulin",NCT01595646,P2,"MCI, AD",37,Change from Baseline in Glucose Tolerance at 16 Weeks,Glucose Tolerance; Cerebral Blood Flow; Plasma Biomarkers of AD; Executive Function Composite; The Alzheimer's Disease Assessment Scale-Cognitive [ADAS-Cog/Alzheimer's Disease Cooperative Study (ADCS)] - MCI Revision; Functional Ability; Cerebral Spinal Fluid (CSF) Biomarkers of AD TTau-P181/Abeta42 Ratio; Cerebral Spinal Fluid (CSF) Biomarkers of AD; Verbal Memory Composite,,2012,2020; Completed,,,
Betaquik MCT supplement,NCT04322461,N/A,"AD, PD",20,"2 m, evaluation before and after intervention",Cognition; Ketones; Endocannabinoids,,2020,2020; Not yet recruiting,,,suppl
Tacrolimus,NCT04263519,P2,"AD, MCI",12,"Baseline, 4 w, 8 w and 12 w","CSF biomarkers of target engagement, AD pathology, and neurodegeneration; Blood biomarkers of target engagement, AD pathology, and neurodegeneration.; Structural neuroimaging of Hippocampal volume.; Functional neuroimaging of default mode network connectivity.; Electroencephalograms (EEG) spectral power; Montreal Cognitive Assessment (MoCA); Neuropsychiatric Inventory Questionnaire (NPIQ); Functional Activities Questionnaire (FAQ); Repeated Battery for the Assessment of Neuropsychological Status",,2020,2020; Not yet recruiting,,,
JNJ-40346527,NCT04121208,P1,"AD, MCI",54,Baseline and visit 3 (Days 14). Serious Adverse Events (Day 14 plus 30 d),Placebo-controlled change from baseline in cerebrospinal fluid (CSF) protein marker concentration levels.; Placebo-controlled change from baseline in CSF and blood biomarker concentration levels; Placebo-controlled change from baseline in amount of CSF extracellular vesicles and cell population.; Measurement of plasma/CSF JNJ-40346527 levels; Measurement of cerebrospinal fluid (CSF) protein marker concentration levels following different JNJ-40346527 doses; Occurrence of adverse events during the study,,2019,2020; Not yet recruiting,,,
Progenitor Stem Cell Culture,NCT00927108,P2,"PD, AD",0,,,,2009,2020; Withdrawn,,,stem
"TMS, Sham-TMS",NCT03243214,N/A,"MCI, PD",41,Blood draw for DNA analysis: Baseline,TMS stimulation applied to the left DLPFC has a quantifiable effect on cognition; Change in structural grey and white matter in the brain at baseline compared to after TMS stimulation; Change in executive functioning measured as BOLD fMRI sequence; Change in levels of biomarkers of interest (alpha-synuclein and BDNF) in serum after TMS stimulation compared to baseline.; Genotyping,,2017,2020; Completed,,,device
"ACI-35.030, JACI-35.054",NCT04445831,P1/P2,"MCI, AD",32,from baseline up to week 74,"Number of participants with Adverse Events (AEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, unlikely, possibly or probably related); Change from baseline in anti-phosphorylated Tau IgG titers in blood; Mean change from baseline in systolic and diastolic blood pressure (mmHg); Mean change from baseline in heart rate (bpm); Mean change from baseline in body temperature (degree Celsius); Number of participants reporting suicidal ideation or behavior using Columbia-Suicide Severity Rating Scale (C-SSRS); Number of participants with abnormal MRI results; Change from baseline in anti-Tau IgG titers in blood; Change from baseline in anti-phosphorylated Tau IgM titers in blood; Change from baseline in anti-Tau IgM titers in blood; Change from baseline of functional performance using Clinical Dementia Rating scale Sum of Boxes (CDR-SB); Change from baseline of cognitive performance using Repeatable Battery for the Assessment of Neuropsychological Status (RBANS); Change from baseline of behavior using Neuropsychiatric Inventory Scale (NPI)",,2020,2020; Recruiting,,,
"DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, Clinical Assessment",NCT03019757,,"AD, PD",76,Post mortem,"Berg Balance Scale (BBS); Mini Mental State Examination (MMSE-1); Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Vocabulary; Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Digit Span; Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Block Design; Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Matrix Reasoning; Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Reliable Digits (embedded measure); Wechsler Memory Scale 3rd ed. (WAIS-3) Spatial Span; Wechsler Memory Scale 3rd ed. (WAIS-3) Logical Memory 1 & 2; Trail Making Test A; Trail Making Test B; Boston Naming Test; Controlled Oral Word Association Test (COWAT)- Animal Naming; Judgment of Line Orientation Standardized Test; Brief Visuospatial Memory Test (BVMT); California Verbal Learning Test (CVLT-2); Wisconsin Card Sorting Task; California Verbal Learning Test (CVLT-2) Forced Choice (embedded measure); Self Administered Gerocognitive Examination- A brief cognitive assessment instrument for mild cognitive impairment and early dementia; Apolipoprotein E (APOE) Genotyping of a whole blood sample; Clinical Dementia Rating Scale (CDR); The Activities of Daily Living (ADL) Standardized Scale; Mayo Fluctuations Scale; Neuropsychiatric Inventory (NPI); Beck Depression Inventory 2nd ed.; The Modified Somatic Perception Questionnaire; The Epworth Sleepiness Scale; Mayo Sleep Questionnaire-Informant; Functional Outcomes of Sleep Questionnaire-10; Part III and IV of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS); Florbetapir (F18-AV-45) positron emission tomography (amyloid PET); Single-photon emission computed tomography (SPECT) with the radioligand [123I]FP-CIT; Positron emission tomography with 2-(18F) fluoro-2-deoxy-d-glucose (FDG-PET); Brain MRI; Polysomnogram; Lumbar Puncture to obtain cerebrospinal fluid (CSF) that will be stored for future potential evaluation of biomarkers; Post-mortem brain donation to The Ohio State University Neurodegenerative Disease Brain Tissue Repository, for clinicopathological correlations",,2017,2020; Recruiting,,,biomarker
"Pittsburgh Compound B (C-11 PiB), F-18 FDG, Tau (18-F-AV-1451)",NCT00950430,P4,"DLB, AD, FTDLD",2500,up to 20 years,"To understand the predictive ability of PiB PET imaging for neurodegenerative diseases.; Using PiB-PET, to ascertain cross-sectionally the magnitude and the spatial distribution of amyloid deposition in the brain in subjects who are clinically classified as CN, MCI, and demented.; To identify the relationship between amyloid burden and the risk of progression from CN at baseline to MCI.; To identify the relationship between amyloid burden and the risk of progression from MCI at baseline to dementia.; To measure longitudinal change in amyloid burden and cognition and characterize the correlation between change on serial PiB-PET measures vs. FDG measures and concurrent change on continuous measures of cognitive performance.",,2009,2020; Enrolling by invitation,,,biomarker
"FDG-PET, ASL-MRI, Lumbar Puncture",NCT01727622,,"MCI, AD",102,2 years,Composite region of interest (ROI) measure of cerebral blood flow (CBF) measured by ASL MRI versus composite ROI measure of cerebral metabolism measured by FDG PET; Prediction of longitudinal change in hippocampal volume; Prediction of longitudinal change in clinical status (i.e. progression to Alzheimer's Disease),,2012,2020; Completed,,,biomarker
"Droxidopa, Midodrine",NCT02897063,P1,"PD, MSA",34,Up to 10 min of head up tilt,Stroke volume,,2016,2020; Recruiting,,,
"EEG, ApoE",NCT03654911,,"MCI, AD",150,2 years,Biomarkers: EEG; Biomarker: ApoE4; Biomarker: Accuracy of digital classifier,,2018,2020; Completed,,,biomarker
Donepezil,NCT01951118,P4,"AD, MCI",121,"Week 0, Week 8, Week 26, Week 52",Measurement of Everyday Cognition (Ecog); Treatment Emergent Symptom Scale (TESS); Wechsler Memory Scale (WMS)-R Digit Span; Boston Naming Test (BNT); Controlled Word Association (CFL); Wechsler Adult Intelligence Scale (WAIS) -III Digit Symbol Subtest; Trail Making Test (Parts A and B); Mini-Mental State Examination - MMSE; Pfeffer Functional Activities Questionnaire (FAQ); Clinician's Interview Based Impression (CIBIC-plus); Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog); Change Over Time in Selective Reminding Test (SRT) Scores,,2013,2020; Completed,,,
"N-831(Traneurocin) 10 mg QD, NA-831 (Traneurocin) 20 mg QD, NA-831 (Traneurocin) 40 mg QD",NCT03538522,P2,"DLB, AD, MCI",126,Week 24,Change from baseline in Clinical Dementia Rating Scale- Sum of Boxes (CDR-SB) score at Week 24; 1. Mean difference between the last (Week 24) and first (Week 2) postdose using Clinical Dementia Rating Scale- Sum of Boxes (CDR-SB) assessment; Assess the change from baseline in ADCS-ADL MCI at Week 24,,2018,2020; Completed,,,
"LY2599666, Solanezumab",NCT02614131,P1,"MCI, AD",50,"Day 85: Pre-dose, 2, 4, 8, 12, 24, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 96, 120, 168, 216, 264, 336, 504, 672 hours post-dose (Part B)",Plasma Amyloid Beta (Aβ1-40 and Aβ1-42) Concentration Part B; Plasma Amyloid Beta1-40 (Aβ1-40 ) Concentration Part A; Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to 168 Hours (AUC 0-168) of LY2599666 Part B; Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC 0-∞) of LY2599666 Part A; Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2599666 Part B; Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2599666 Part A; Number of Participants With One or More Serious Adverse Event (SAE) Considered by the Investigator to be Related to Study Drug Administration,,2015,2020; Terminated,,,
Nelotanserin,NCT02708186,P2,"PD, DLB",34,28 d,Change in the Frequency of REM Sleep Behavior Disorders (RBD) From Baseline to the End of the Treatment Period (28 Days) Based on a Clinical Evaluator.,,2016,2020; Completed,,,
Insulin (Humulin® R U-100),NCT01767909,P2/P3,"AD, MCI",240,Baseline and Month 12,Change in CSF Biomarkers of AD; Change in Hippocampal and Entorhinal Atrophy as Measured by Magnetic Resonance Imaging (MRI); Change in Cognitive Deficit as Measured by Clinical Dementia Rating - Sum of Boxes (CDR-SB); Change in Daily Functioning as Measured by the ADCS-MCI Activities of Daily Living (ADCS-ADL-MCI); Change in Memory Composite as Measured by Story Recall (Immediate Paragraph Recall and Delayed Paragraph Recall) and Free and Cued Selective Reminding Test (FCSRT); Change in Global Measure of Cognition as Measured by the Alzheimer's Disease Assessment Scale-Cognitive 12 (ADAS-Cog12),,2013,2020; Completed,,,
"Placebo, Insulin aspart",NCT02462161,P1,"MCI, AD",24,Baseline and week 12,"Change in cognition; Cerebral spinal fluid (CSF) and blood amyloid-beta, tau protein, and inflammatory markers; MRI measure of cortical thickness in Alzheimer's disease (AD) -vulnerable regions",,2015,2020; Completed,,,
"Methylene Blue, FD&C Blue # 2, Phenazopyridine hydrochloride",NCT02380573,P2,"AD, MCI",117,"baseline, change from baseline at 2 w ± 3 d, change from baseline at 12 w ± 3 d",Working memory task; Working memory task response; Episodic memory task; Episodic memory task response; Sustained attention task; Sustained attention task reaction time; Neuropsychological battery composite score; Cerebral blood flow measures; Functional Connectivity measures; CO2 challenge,,2015,2020; Suspended,,,
"Anti-Parkinson medication, Deep Brain Stimulation",NCT02994719,,"HD, CBD, MSA, PSP, PD",120,"through study completion, an average of 1 year",Gait speed; Swing duration; Stance duration; Cadence; Stride length,,2016,"2020; Active, not recruiting",,,delete
"Memantine, Donepezil, Measurement of serum level of anti-dementia drug",NCT04117178,P4,"PD, DLB, AD",110,For participants in the standard of care arm APOe4 allele status will be determined 1 year after enrollment. APOe4 allele status will be determined at the 6 month follow-up for participants in the intervention arm.,Change of Mini Mental State Examination (MMSE) test result; Change of Adenbrooke's Cognitive Exam (ACE) test result; Change of Neuropsychiatric Inventory Questionnaire (NPI-Q) score result; Change of Disability Assessment for Dementia (DAD) score result; Change of Clinical Global Impression (CGI) score result; Serum level of donepezil; Serum level of memantine; Level of compliance to treatment; Change in Geriatric Depression Scale (GDS) symptoms score; Change in quantitative electroencephalogram (qEEG); Cyp2D6 gene test; genetic test for BcHE K variant; genetic test for APOe4 allele status.,,2019,2020; Recruiting,,,
RVT-101 35 mg,NCT02910102,P2,"DLB, AD, PD",38,"Baseline, 2 w",Change in Gait Measurements (cm/Sec) Under Dual Task Condition From Baseline to the End of Each Double-blind Treatment Period Based on Computerized Gait Assessment Tools.; Change From Baseline in Gait Speed (cm/Sec) Measurements From Baseline to the End of Each Double-blind Treatment Period Based on Computerized Gait Assessment Tools.,,2016,2020; Completed,,,
"Placebo, TPI 287 2 mg/m2, TPI-287 20 mg/m2, TPI-287 6.3 mg/m2",NCT02133846,P1,"CBD, PSP",44,Screening and 2 Weeks after last infusion,CSF biomarkers; Maximum tolerated dose of TPI-287 in patients with primary 4RT; CBS or PSP.; TPI-287 levels in blood plasma and cerebrospinal fluid; Brain MRI scan; Degree of disability; Cognition; Behavior,,2014,2020; Completed,,,
Insulin glulisine,NCT02503501,P2,"AD, MCI",49,Baseline and 6 m,Change in Functional Performance as Measured by the Functional Activities Questionnaire (FAQ); Change in Functional Performance as Measured by the Clinical Dementia Rating (CDR) Scale; Change in Cognition as Measured by the Alzheimer's Disease Assessment Scale - Cognitive 13 (ADAS-Cog 13),,2015,2020; Terminated,,,
Valaciclovir 500Mg Tablet,NCT02997982,P2,"MCI, AD",33,Treatment day 28,Cerebrospinal fluid (CSF) Total Tau; Cerebrospinal fluid (CSF) Neurofilament light chain (NFL); Cerebrospinal fluid (CSF) phosphorylated Tau (p-Tau); Cerebrospinal fluid (CSF) Amyloid beta 1-42; PET/CT: [18F]-FHBG accumulation within the central nervous system (CNS); PET/CT: Location of [18F]-FHBG accumulation; PET/CT: [18F]-FHBG accumulation; Mini Mental State Examination - Swedish Revision (MMSE-SR); Cerebrospinal fluid (CSF) acyclovir concentration; Cerebrospinal fluid (CSF) 9-carboxymethoxymethylguanine (CMMG) concentration; Serum acyclovir concentration; Serum 9-carboxymethoxymethylguanine (CMMG) concentration; Proportion completing the [18F]-FHBG-PET/CT investigations; Proportion completing the 28 days treatment with valaciclovir at specified doses,,2016,2020; Completed,,,
deferiprone,NCT02880033,N/A,"ALS, PD",90,12 m,hydroxyl radical measured; adenosine triphosphate production measured by seahorse; oxygen consumption measured by seahorse; free reactive iron (ferrous iron); lipid peroxidation measured by Fluorescence-activated cell sorting,,2016,2020; Completed,,,
repetitive transcranial magnetic stimulation (rTMS),NCT04294888,N/A,"MCI, AD",40,up to 5 w,Paired Associative Face Name Memory Test; Changes in intrinsic functional connectivity,,2020,2020; Recruiting,,,device
"Metabolic Cofactor Supplementation, Sorbitol",NCT04044131,P2,"AD, PD",120,4 w and 12 w,"Mini Mental State Examination (MMSE); Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog); Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL); Changes in creatinine kinase (CK) level from baseline; Change in thyroid-stimulating hormone (TSH) level from baseline; Unified Parkinson's Disease Rating Scale (UPDRS); Volumetric Magnetic resonance Imaging (MRI) and resting state functional magnetic resonance imaging (rest-fMRI); Neuropsychiatric Inventory (NPI); Montreal Cognitive Assessment (MoCA); Changes in serum omic profile from baseline; Microbiota analysis; Monitoring of adverse events; Change in heart rate from baseline; Change in blood pressure from baseline; Change in waist and hip circumference from baseline; Change in body weight from baseline; Change of complete blood count from baseline; Changes in liver function tests (alkaline phosphatase (ALP), alanine aminotransferase (ALT), Aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), total and direct Bilirubin, Albumin) from baseline; Changes in blood lipid levels (total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL-C), high density lipoprotein (HDL-C)) from baseline; Changes in kidney function tests (creatinine, urea, urate, sodium, potassium) from baseline; Change in blood insulin level from baseline; Change in glycated haemoglobin (HbA1c) level from baseline; Changes in blood glucose levels from baseline",,2019,2020; Recruiting,,,
Deferiprone 600mg delayed release tablets,NCT03234686,P2,"AD, MCI",171,12 m,"Efficacy of Deferiprone; Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability); Brain Iron Levels; The effect of Deferiprone on the episodic memory, executive function and attention composites; The Association with Iron levels in the Brain and Cognitive Decline; The Potential for Brain Iron Load to be Used to Stratify Responsiveness to Deferiprone; The Potential for APOE Genotype to be Used to Stratify Responsiveness to Deferiprone",,2017,2020; Recruiting,,,
Flutemetamol (Vizamyl),NCT02353949,P3,"MCI, AD",11,Six Months after initiation of standard treatment,Comparisons of change from pre-treatment assessment of ADCS-CGIC after 6 months in clinical constellations defined by clinical diagnosis and Flutemetamol-status; Change from pre-treatment assessment on the decision regret scale after three months; Change from pre-treatment assessment on the decision regret scale after six months; Change of ADAS-cog 11 score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.; Change of ADCS-ADL score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.; Change of ADCS-CGIC score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.; Change of MMSE score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.; Comparisons of change from pre-treatment assessment of ADAS-Cog-11 after 6 months in clinical constellations defined by clinical diagnosis and Flutemetamol-status; Comparisons of change from pre-treatment assessment of ADCS-ADL after 6 months in clinical constellations defined by clinical diagnosis and Flutemetamol-status; Comparisons of change from pre-treatment assessment of MMSE after 6 months in clinical constellations defined by clinical diagnosis and Flutemetamol-status,,2015,2020; Terminated,,,biomarker
NBMI,NCT04184063,P2,"PSP, MSA",16,"Day 56, 57","Pharmacokinetic parameters derived from plasma concentrations of NBMI: AUC0-∞; Pharmacokinetic parameters derived from plasma concentrations of NBMI: AUC%Extrap,obs; Changes in Non-Motor Symptoms assessment scale (NMSS) individual scale from baseline in MSA patients compared to placebo treatment; Changes in Progressive Supranuclear Palsy rating Scale (PSPRS) individual scales scores from baseline in PSP patients compared to placebo treatment; Changes in FAB individual scales scores from baseline in PSP patients compared to placebo treatment; Pharmacokinetic parameters derived from plasma concentrations of NBMI: t1/2; Pharmacokinetic parameters derived from plasma concentrations of NBMI: λz; Changes in Unified Multiple System Atrophy Rating Scale (UMSARS) individual scale from baseline in MSA patients compared to placebo treatment; Changes in QOL individual scores from baseline by MSA questionnaire in MSA patients; Changes in QOL individual scores from baseline by MSA questionnaire in MSA patients using Visual Analog score; Changes in QOL individual scores from baseline by EQ-5D score in PSP patients compared to placebo treatment; Changes in Parkinson's Disease Fatigue Score (PFS) score from Baseline - V1 to V2 (D29) and V1 to V5 (D57) in PSP and MSA patients compared to placebo treatment; Changes in Beck's Depression Inventory (BDI) scale (MSA patients) score from Baseline V1 to V2 (D29) and to V4 (D57) compared to placebo treatment; Changes in Geriatric depression scale (GDS) (PSP patients) score from Baseline - V1 to V2 (D29) and to V4 (D57) compared to placebo treatment; Frequency, type and severity of adverse events compared to placebo treatment .; Percentage of NBMI-treated patients who develop a response to NBMI.; Changes from baseline in brain metabolism as evaluated with Fluorodeoxyglucose Positron Emission Tomography (FDG PET) CT brain imaging compared to placebo treatment; Changes from baseline in brain iron levels as detected with Magnetic Resonance Imaging (MRI) imaging methods compared to placebo treatment; Pharmacokinetic parameters derived from plasma concentrations of NBMI: Maximum Plasma Concentration [Cmax]; Pharmacokinetic parameters derived from plasma concentrations of NBMI: AUC0-t; Pharmacokinetic parameters derived from plasma concentrations of NBMI: T max",,2019,2019; Recruiting,,,
Droxidopa,NCT03446807,P2,"MSA, PD, PSP",32,Week 29,Efficacy of Droxidopa on fatigue in subjects with Parkinsonism as determined by completion of Visual Analogue Fatigue Scale (VAFS); Efficacy of Droxidopa on motor and non-motor symptoms of Parkinsonism as determined by the Unified Parkinson's Disease Rating Scale (UPDRS),,2018,2019; Not yet recruiting,,,
Neuraceq,NCT04055532,,"DLB, PD, AD, ALS, FTDLD, MCI",0,2-5 Years,Performance on Batteries of Cognitive Tests,,2019,2019; Withdrawn,,,biomarker
11C-PBR28,NCT02702102,P2,"PD, DLB",5,1 year,Absolute 11C-PBR28 binding (total distribution volume corrected for free fraction in plasma); Relative 11C-PBR28 binding,,2016,2019; Completed,,,biomarker
Allopregnanolone injection (intravenous solution),NCT02221622,P1,"AD, MCI",24,Baseline and Week 13,Safety profile: Adverse events; Safety profile: Clinical laboratory measurements; Safety profile: ARIA; Safety profile: Physical and neurological examination; Tolerability - Maximum tolerated dose (MTD); Pharmacokinetic profile after single and multiple doses: Maximum Concentration (Cmax); Pharmacokinetic profile after single and multiple doses: time attain to Cmax (Tmax); Pharmacokinetic profile after single and multiple doses: Area under the curve (AUC); Pharmacokinetic profile after single and multiple doses: Drug Clearance (CL); Pharmacokinetic profile after single and multiple doses: apparent volume of distribution at steady state (Vss); Cognitive tests (ADAS-Cog; MMSE/MoCA; ADCS-CGIC; CogState); Brain MRI volumetrics,,2014,2019; Completed,,,
VX-745,NCT02423122,P2,"MCI, AD",16,Day 84,Number of 11C-PiB Responders; Percent Change From Baseline in Amyloid Plaque Burden by 11C-PiB PET; Wechsler Memory Scale (WMS) Delayed Recall Composite; Wechsler Memory Scale (WMS) Immediate Recall Composite,,2015,2019; Completed,,,
"Verubecestat 12 mg (Parts 1 and 2), Verubecestat 40 mg (Parts 1 and 2)",NCT01953601,P3,"AD, MCI",1454,Baseline and Week 104 in Part 1,Part 1 (Base Study). Mean Percent Change From Baseline in Cerebrospinal Fluid (CSF) Total Tau Concentration at Week 104; Part 1 (Base Study). Least Squares Mean Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment Version) (ADCS-ADL MCI) Score at Week 104; Part 1 (Base Study). Least Squares Mean Change From Baseline in Composite Cortical Amyloid Standard Uptake Value Ratio (SUVR) Assessed With Amyloid Tracer [18F]Flutemetamol Using Positron Emission Tomography (PET) Imaging at Week 104; Part 1 (Base Study). Least Squares Mean Percent Change From Baseline in Total Hippocampal Volume (THV) at Week 104; Part 1 (Base Study). Least Squares Mean Change From Baseline in the 3-Domain Composite Cognition Score (CCS-3D) at Week 104; Part 1 (Base Study). Estimated Least Squares Mean Difference Between the Last (Week 104) and First (Week 13) Post-dose CDR-SB Assessment; Part 1 (Base Study). Event-Rate Per 100 Participant Years for Progression to a Clinical Diagnosis of Probable AD Dementia; Part 2 (Extension Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE); Part 2 (Extension Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE); Part 1 (Base Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE); Part 1 (Base Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE); Part 2 (Extension Study). Mean Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 130; Part 1 (Base Study). Least Squares Mean (LSM) Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 104,,2013,2019; Terminated,,,
"MK-4334, Donepepzil",NCT03740178,P1,"MCI, AD",12,"Day 14: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360, and 480 hours after MK-4334 administration",Number of Participants Experiencing an Adverse Event (AE); Number of Participants Discontinuing Study Treatment due to an Adverse Event; Plasma Steady State Concentration at 24 Hours (C24) of MK-4334; Plasma Steady State Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of MK-4334; Plasma Steady State Maximum Concentration (Cmax) of MK-4334; Plasma Steady State Apparent Half-Life (t1/2) of MK-4334; Plasma Steady State Time to Maximum Concentration (Tmax) of MK-4334; Plasma Steady State Apparent Clearance (CL/F) of MK-4334; Plasma Steady State Apparent Volume of Distribution (Vz/F) of MK-4334,,2018,2019; Not yet recruiting,,,
"Amyvid PET Scan, T807 PET scan",NCT02266563,,"MCI, CTE",46,2 years,Uptake of [18F]T807 in the brain; Uptake of [18F]AV-45 in the brain; Neuropsychological data composite score,,2014,2019; Completed,,,biomarker
"davunetide (AL-108, NAP)",NCT01056965,P1,"PSP, CBD, FTDLD",12,12 w,"Safety evaluations will be performed by recording clinical adverse events at each study visit. Clinical laboratory, ECGs, physical examinations will be conducted.; PSP Rating Scale; Clinician's Global Impression (CGI-ds); Schwab and England Activities of Daily Living scale (SEADL); MRI brain ventricular volume; Repeatable Battery for the Assessment of Neuropsychological Status (RBANS); Unified Parkinson's Disease Rating Scale (UPDRS); Neuropsychiatric Inventory (NPI); Geriatric Depression Scale (GDS); CSF biomarkers will assess total tau, phosphorylated tau, and amyloid beta peptide (1-42); Saccadic Eye movements - vertical and horizontal total saccade time; Clinical Dementia Rating (CDR); Functional Activities Questionnaire (FAQ)",,2010,2019; Completed,,,
[123I]CLINDE,NCT00612872,P1,"AD, PD",46,6 mos,"To assess the dynamic uptake and washout of 123-I CLINDE, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and subjects with Alzheimer (AD) or Parkinson disease (PD).",,2008,2019; Terminated,,,biomarker
Nelotanserin,NCT02871427,P2,"PD, DLB",80,24 w,"Long-term safety and tolerability will be evaluated based on incidence of adverse events (AEs) and significant changes in physical examinations, vital signs, ECGs, and clinical laboratory assessments over time during treatment.; Long-term effectiveness will be evaluated based on change in the frequency and severity of visual hallucinations (as recorded by patient's caregiver) and/or REM sleep behaviors (based on a clinical evaluator) over time during treatment.",,2016,2019; Terminated,,,
Intranasal Insulin,NCT02064166,P2,"PD, MSA",15,Baseline and post-treatment,"Modified Hoehn and Yahr Scale; Beck Depression Inventory Score (BDI); Cognitive Impairment Using Montreal Cognitive Assessment (MoCA); Brief Visuospatial Memory Test-Revised (BVMT-R); Gait Analysis (4-meter Test); Unified Parkinson's Disease Rating Scale Part III (UPDRS Part III); Change in Verbal Fluency FAS (F, A or S Words) Total Score",,2014,2018; Completed,,,
Dabigatran,NCT03752294,P1,"AD, MCI",40,24-m,Evaluate dabigatran efficacy in MCI and mild AD population using changes in targeted plasma and CSF biomarker levels at 9 and 21 months; Demonstrate a reduction in decline of cognitive function related to physical functioning in placebo arm after crossing over to 12-months of active treatment; Changes in cognitive performance in placebo arm after cross-over to open-label treatment phase; Safety and tolerability of dabigatran in experimental population (MCI and mild AD populations) based on reported serious and adverse events; Evaluation of cognitive performance in placebo arm after cross-over to open-label treatment phase,,2018,2018; Not yet recruiting,,,
"Warfarin, Dimebon",NCT00827034,P1,"HD, AD",14,7+18 d,"Single dose pharmacokinetics (Cmax, AUCinf) of warfarin 25 mg with and without co-administration of steady-state Dimebon 20 mg TID in healthy adult subjects.; Single dose pharmacodynamics (INRmax, AUC-INR) of warfarin 25 mg with and without co-administration of steady-state Dimebon 20 mg TID in healthy adult subjects.; Safety and tolerability ( adverse event monitoring, physical examinations, vital signs, ECG's and clinical laboratory tests) of multiple doses of Dimebon 20 mg TID with a single dose of warfarin 25 mg in healthy adult subjects.",,2009,2018; Completed,,,
MK-8931,NCT02910739,P1,"AD, MCI",16,Up to 14 d following MK-8931 40 mg administration.,Number of Participants Discontinuing Study Due to an Adverse Event; Number of Participants Experiencing an Adverse Event; Apparent Volume of Distribution of MK-8931 During the Terminal Phase After Extravascular Administration (Vz/F); Apparent Terminal Half-Life of MK-8931 (t1/2); Time to Maximum Observed MK-8931 Plasma Drug Concentration (Tmax); Apparent Clearance of MK-8931 After Extravascular Administration (CL/F); Plasma Concentration of MK-8931 at 24 Hours (C24hr); Area Under the Concentration Versus Time Curve of MK-8931 From 0 to 24 Hours (AUC0-24hr); Area Under the Concentration Versus Time Curve of MK-8931 From 0 to the Time of the Last Quantifiable (Above LLOQ) Sample (AUC0-last); Maximum Observed Plasma Concentration of MK-8931 (Cmax); Area Under the Concentration Versus Time Curve of MK-8931 From 0 to Infinity (AUC0-∞),,2016,2018; Completed,,,
EEG scan,NCT03644043,,"MCI, AD",2000,10 d,Patient meeting Appropriate Use Criteria (AUC) with EEG brain scan - P300 and P50 will be measured for correlation between P300 and P50 with amyloid deposition.,,2018,2018; Unknown status,,,biomarker
Exendin-4 SC,NCT01255163,P2,"MCI, AD",57,18 m,Number of Participants With Incidence of Nausea; Body Mass Index (BMI); Cerebrospinal Fluid Amyloid-beta 42 (CSF Abeta42); Cerebrospinal Fluid phospho181-tau (CSF p181-tau); Cerebrospinal Fluid (CSF) Total Tau; Clinical Dementia Rating (CDR) Sum of Boxes; Clinical Dementia Rating (CDR) Global Score; Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog70); Mini Mental State Examination (MMSE),,2010,2018; Terminated,,,
"Neurocognitive battery, MRI, Blood tests, EEG with event-related potential (ERP), Amyloid PET CT",NCT03275363,,"MCI, AD",500,1 year,Cognitive decline; Functional decline; Neuropsychiatric decline; Quality of life decline; Change in cognitive impairment status,,2017,2017; Recruiting,,,delete
Exelon Patch (rivastigmine transdermal system),NCT01519271,P4,"MCI, PD",28,The MoCA was administered in the beginning and end of each study phase.,Montreal Cognitive Assessment (MoCA); Alzheimer's Disease Cooperative Study- Clinical Global Impression Change (ADCS-CGIC),,2012,2017; Completed,,,
"transcranial magnetic stimulation, MRI imaging, EEG recording, Neuropsychological examination",NCT02236832,N/A,"FTDLD, PSP",225,day of inclusion (one day),Performance in the implicat task; Performance in the Similitude task; recording of EEG; Analysis of MRI,,2014,2017; Recruiting,,,device
AZD5213,NCT01548287,P2,"AD, MCI",164,Baseline and Week 4.,"Change From Baseline in Sleep Efficiency After 4 Weeks of Treatment, Based on Actigraphy Recording.; Change From Baseline in Latency of Persistent Sleep After 4 Weeks of Treatment, Based on Actigraphy Recording.; Change From Baseline in Night Total Sleep Time After 4 Weeks of Treatment, Based on Actigraphy Recording.; Change From Baseline in Latency to Persistent Sleep After 4 Weeks of Treatment, Based on PSG Measurements.; Change From Baseline in Sleep Efficiency After 4 Weeks of Treatment, Based on PSG Measurements.; Change From Baseline in Total Sleep Time (TST) After 4 Weeks of Treatment, Based on PSG Measurement.",,2012,2017; Completed,,,
Incobotulinum Toxin A,NCT01565395,P2,"PD, ALS",0,7 m,Change in objectively measured salivary volume between baseline and one month post-injection in the Xeomin group as compared to placebo,,2012,2017; Withdrawn,,,
[123I]MNI-420,NCT00970229,P1,"HD, PD",19,1 year,"To evaluate [123I]MNI-420 as a quantitative imaging outcome measure of A2aR activity in PD, HD, and healthy subjects",,2009,2017; Completed,,,bimarker
SRT,NCT02814201,,"PD, HD",55,Day 0,SRT,,2016,2016; Completed,,,
"Lombar Punction, Magnetic Resonance Imaging (MRI), Positron-Emission Tomography (TEP) /(FDG), Psychiatric tests, Neuropsychological Tests, Apolipoprotein (ApoE) detection",NCT02843906,N/A,"MCI, AD",180,40 minutes,Functionnal/Cognitive evaluation; Psychatric evaluation; Brain MRI,,2016,2016; Unknown status,,,delete
AVP-923,NCT00056524,P3,"AD, PD",600,,emotional control,,2003,2016; Completed,,,
ABT-957,NCT02573740,P1,"MCI, AD",8,84 d,Percentage of participants reporting treatment-emergent adverse events; Level of spectrin breakdown product-145 (SBDP-145),,2015,2016; Terminated,,,
AQW051,NCT00582855,P2,"AD, MCI",54,Throughout the study,"Validated computerized cognitive assessment scores; Validated computerized cognitive assessment scores, the different scores from the Alzheimer's Disease Assessment Score-cognitive subscale (ADAS-Cog), Quality of Life-Alzheimer disease scale and the Disability Assessment for Dementia scale",,2007,2016; Terminated,,,
"active Deep TMS, sham Deep TMS",NCT02734485,N/A,"PD, PSP",20,"evaluation time (pre-stimulation: T0 for first period, T2 for second period; post-stimulation (after four w of treatment): T1 for first period, T3 for second period",Change in PSP rating scale total score between baseline evaluations (T0 orT2) and end of treatment (T1 or T3); Change in MoCA total score between baseline evaluations (T0 orT2) and end of treatment (T1 or T3); Change in PDQ 39 total score between baseline evaluations (T0 orT2) and end of treatment (T1 or T3); Change in NMS total score between baseline evaluations (T0 orT2) and end of treatment (T1 or T3); Change in Hamilton rating scale for depression total score between baseline evaluations (T0 orT2) and end of treatment (T1 or T3),,2016,2016; Completed,,,device
"neuropsychologic assessment, [18F]AV-45 PET, 18-FDG PET, MRI",NCT01325259,P2,"AD, MCI",54,inclusion,Standard Uptake Value Ratios (SUVr),,2011,2016; Completed,,,bimarker
[F18]-FDDNP,NCT02214862,Early P1,"PD, PSP",40,18 m,"To assess the Relative Volume of Distribution of [18F]-FDDNP in individuals with unclassifiable parkinsonism, and to try to correlate their eventual clinical diagnosis with baseline PET findings.; to assess the uptake of [18F]-FDDNP in cases clinically defined of progressive supranuclear palsy and multi-system atrophy; To assess the ability to detect in vivo underlying tau pathology in unclassifiable parkinsonism by means of PET -[18F]-FDDNP.",,2014,2016; Completed,,,bimarker
Memantine,NCT00630500,P2,"PD, DLB",75,Month 3 and 6,"Cognitive Drug Research test; Neuropsychiatric Inventory; Unified Parkinson's Disease Rating Scale, part III; Epworth Sleep Scale; Stavanger Sleep Scale; Clinical Global Impression of Change; MMSE; Alzheimer's QUick Test",,2008,2015; Completed,,,
Lithium,NCT00703677,P1/P2,"CBD, PSP",17,28 w,Frontal Assessment Battery (FAB): Change From Baseline; Unified Parkinson Disease Rating Scale (UPDRS) Motor Subscale Score: Change From Baseline; PSP-Quality of Life Scale (QoL):Change From Baseline; Geriatric Depression Scale(GDS)-15:Change From Baseline; PSP Rating Scale Score: Change From Baseline; Change in Glycogen Synthase Kinase (GSK)-3 Beta Activity; Change in Brain-Derived Neurotrophic Factor (BDNF) in CSF; Changes in Amount of Tau and Phosphorylated Tau in Cerebral Spinal Fluid (CSF); Study Drug Compliance; Ability to Tolerate Lithium Carbonate,,2008,2015; Completed,,,
Posiphen® tartrate capsules,NCT01072812,P1,"AD, MCI",5,10 d,Pharmacokinetics; Pharmacodynamics; Biomarkers; Safety,,2010,2015; Terminated,,,
"es-citalopram, Memantine",NCT01876823,P2/P3,"AD, MCI",60,"Baseline, Week 48",Conversion to Dementia Using Clinical Dementia Rating (CDR); Change in Clinical Global Impression - Cognitive Change; Change in Clinical Global Impression - Depression Change; Change in Treatment Emergent Side Effects (TESS); Change in 24-item HAMD; Change in Trails A; Change in Trails B; Change in Selective Reminding Test - Delayed Recall (SRT-DR); Change in Wechsler Memory Scale-III (WMS-III); Change in Selective Reminding Test - Total Immediate Recall (SRT-IR),,2013,2014; Completed,,,
"florbetapir 18F, 18F-FDG",NCT01890343,P2,"FTDLD, AD",34,50-60 minutes after injection,Quantitative Amyloid Image Assessment; Qualitative Amyloid Image Assessment,,2013,2014; Completed,,,biomarker
Minocycline,NCT01463384,P2,"AD, MCI",13,"Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged)","Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).; Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC); Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)",,2011,2014; Completed,,,
"Droxidopa, Carbidopa, Entacapone",NCT00547911,P1/P2,"MSA, PD",14,Up to 24 hours after receiving drug(s),"Heart Rate After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone; Diastolic Blood Pressures After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone; Systolic Blood Pressures After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone; Plasma DHPG Concentrations After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone; Plasma DHMA Concentrations After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone; Plasma Norepinephrine Concentrations After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone; Plasma LDOPS Concentrations After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone",,2007,2014; Terminated,,,
testosterone gel,NCT00539305,P3,"AD, MCI",22,"Baseline, Month 3, Month 6",Short-Form Health Survey (SF-36); Geriatric Depression Scale (GDS); Cognitive Changes Measured by Neuropsychological Tests: Rey Auditory Verbal Learning Test; Behavioral & Mood Measure: Profile of Mood States (POMS),,2007,2014; Completed,,,
Insulin LISPRO,NCT01636596,N/A,"AD, MCI",0,30 w,cerebral glucose metabolism; cognition; general clinical improvement; basal metabolism,,2012,2014; Withdrawn,,,
EVP-0962,NCT01661673,P2,"AD, MCI",52,0-36 hours post dose,"The number of adverse experiences reported by subjects and/or observed by investigator and repeated clinical evaluations of physical examinations, vital signs, 12-lead ECG (electrocardiogram), and lab tests (hematology, chemistry, urinalysis); To measure the rate of synthesis of Amyloid Beta in cerebral spinal fluid of healthy subjects; To measure the concentration of Amyloid Beta in cerebral spinal fluid; To measure the rate of synthesis of Amyloid Beta and steady-state levels in the cerebral spinal fluid in MCI or early Alzheimer's disease patients; To determine single-and repeat-dose EVP-0962 pharmacokinetics in cerebral spinal fluid and plasma",,2012,2014; Completed,,,
Memantine,NCT00855686,P4,"DLB, PD",199,,No primary or secondary outcome measures are defined. This study is exploratory (see above under detailed description).,,2009,2013; Completed,,,
"Placebo, DAOI-B",NCT01600469,P2,"AD, MCI",86,"Week 0, 24","Change from baseline in Alzheimer's disease assessment scale-cognitive subscale in week 8, 16 and 24; Change from baseline in Mini Mental Status Examination at week 8, 16 and 24; Change from baseline in Instrumental Activities of Daily Living at week 8, 16 and 24; Change from baseline in Verbal learning and memory at week 24; Change from baseline in Digit Span subtest of the Wechsler Memory Scale at week 24",,2012,2013; Completed,,,
CerefolinNAC®,NCT01370954,,"AD, MCI",204,"Baseline, Week 6 and Week 12",To determine overall patient satisfaction with CerefolinNAC® using a 9-point satisfaction scale; To determine if CerefolinNAC® affects a subject's quality of life as measured by the Quality of Life-Alzheimer's Disease Scale (QOL-AD),,2011,2013; Completed,,,
"dimebon, alprazolam",NCT00975481,P1,"HD, AD",36,"0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose",Other Subjective Effects- Addiction Research Center Inventory (ARCI) Benzedrine Group (BG): Maximum Effect (Emax) and Minimum Effect (Emin); Other Subjective Effects- Drug Similarity; Other Subjective Effects- Any Drug Effects: Peak Effect (Maximum Effect [Emax]); Sedative Effects- Alertness/Drowsiness: Minimum Effect (Emin); Sedative Effects- Addiction Research Center Inventory (ARCI) Pentobarbital Chlorpromazine Group (PCAG): Maximum Effect (Emax); Negative Effects- Addiction Research Center Inventory (ARCI) Lysergic Acid Diethylamide (LSD): Maximum Effect (Emax); Negative Effects- Bad Drug Effects: Peak Effect (Maximum Effect [Emax]); Positive Effects- High VAS: Peak Effect (Maximum Effect [Emax]); Positive Effects- Good Drug Effects: Peak Effect (Maximum Effect [Emax]); Positive Effects- Addiction Research Center Inventory (ARCI) Morphine Benzedrine Group (MBG): Maximum Effect (Emax); Balance of Effects- Subjective Drug Value (SDV): Maximum Effect (Emax); Balance of Effects- Good and Bad Effects VAS: Peak Effect (Maximum Effect [Emax]) and Minimum Effect (Emin); Balance of Effects- Take Drug Again VAS: Peak Effect (Maximum Effect [Emax]); Balance of Effects- Overall Drug Liking VAS: Peak Effect (Maximum Effect [Emax]) and Minimum Effect (Emin); Balance of Effects- Drug Liking VAS: Peak Effect (Maximum Effect [Emax]) and Minimum Effect (Emin),,2009,2013; Completed,,,
"Placebo Comparator, insulin detemir",NCT01547169,P2,"AD, MCI",60,Change from Baseline in Visual Working Memory at 3 Weeks,Verbal Memory Composite; Neuropsychological Test of Executive Function 1; Glucose Tolerance; Functional Ability; Plasma biomarkers of AD; Neuropsychological Test of Executive Functioning 2; Neuropsychological Tests of Visual Working Memory,,2012,2012; Completed,,,
Ramelteon,NCT00907595,N/A,"HD, DLB, PD",0,2 w pre intervention; 4 w of the intervention; 2 w after intervention,"Sleep efficiency and other actigraphy derived sleep parameters; UHDRS, UPDRS, cognitive measures, mood symptoms, aggression measures, functional ability.",,2009,2012; Withdrawn,,,
Regular Insulin,NCT00438568,P2,"AD, MCI",173,"every 8 w for 16 w, again at 8 w post-treatment (24 w)",Changes in cognition; glucose metabolism; plasma biological markers; CSF biological markers; cerebral glucose metabolism,,2007,2012; Completed,,,
HPP854,NCT01482013,P1,"MCI, AD",7,Day -6 to Day 35,Number of Participant Adverse Events; Evaluation of participant plasma HPP854 concentrations; Change in cerebrospinal fluid concentration of Amyloid-Beta,,2011,2012; Terminated,,,
"Supressi. T-Diet plus Range, High Protein. T-Diet plus Range",NCT01192529,N/A,"PD, AD",184,8 m,Nutritional and cognitive status in elderly people; Biochemical parameters measure,,2010,2012; Unknown status,,,suppl
Dimebon,NCT00825084,P1,"HD, AD",45,72 hours post last dose,"plasma drug concentrations; Safety will be including physical/neurological examination findings, clinical safety laboratory assessments, 12-lead ECGs, vital sign measurements and adverse event monitoring",,2009,2011; Completed,,,
"Dimebon IR, Dimebon Transdermal",NCT00990613,P1,"HD, AD",19,4 to 6 d,"Pharmacokinetic endpoints include dimebon area under the curve from 0 to the last quantifiable concentration (AUClast) and dimebon area under the curve from 0 to infinity (AUCinf) as permitted by data; Safety endpoints include subjective symptoms/objective findings (including skin irritation), clinical safety laboratory assessments, 12 lead ECGs, and supine vital signs.",,2009,2010; Completed,,,
"Dimebon IR Tablet, Dimebon MR1, Dimebon MR2, Dimebon MR3, Dimebon MR4",NCT00988624,P1,"HD, AD",20,"Day 1-3 of Period 1, 2, 3, 4, or 5","PK endpoints for dimebon and M7 (where appropriate) for each formulation: AUC0-24, AUC0-24(dn), AUCinf (as data permit) AUCinf(dn), AUClast, AUClast(dn), Tlag, Cmax, Tmax, and t1/2 (as data permit).; Safety and tolerability for each formulation (AEs, ECG, vital signs, safety labs)",,2009,2010; Completed,,,